405 results about "Thymus Glands" patented technology

A cell surface molecule that is expressed specifically in thymocytes, lymphocytes activated by ConA-stimulation, and peripheral blood lymphocytes. This molecule is involved in signal transmission of the secondary signal (costimulatory signal) essential for the activation of lymphocytes such as T cells and regulates functions of activated lymphocytes such as activated T cells. Disclosed are an antibody or a portion thereof, which binds to a polypeptide of the cell surface molecule, a polypeptide fragment thereof, or a fusion polypeptide comprising the fragment; a cell secreting the antibody or its portion; a pharmaceutical composition comprising the antibody; and methods of using the compositions for therapeutic, diagnostic and/or experimental purpose.

The invention belongs to the technical field of medicament, and particularly relates to preparation and application of phycocyanin extract. The phycocyanin extract is prepared by the following steps of: crushing spirulina cell walls of spirulina powder to obtain a crude extract by a repeated freeze-thawing method at the temperature of between 20 DEG C below zero and 4 DEG C; depositing the crude extract to obtain a crude protein extract by using 50 to 60 mass percent of ammonium sulfate; and then extracting and purifying the crude protein extract by adopting double aqueous phases, and removing salt by using excess infiltration to obtain phycocyanin extract solution. The phycocyanin extract mainly comprises phycocyanin, and the aqueous solution of the phycocyanin extract has the absorbance characteristics that A620/280 is slightly equal to 3.0+/-0.2 and A620/650 is slightly equal to 2.2+/-0.1. The phycocyanin extract is obtained by mainly combining the processes of ammonium sulfate deposition, double aqueous phase extraction, dialysis and salt removal and the like; and the phycocyanin extract administrated to S180 sarcoma mice with different dosages shows good tumor inhibiting effect and has no obvious toxicity on the spleen and the thymus gland.

The present disclosure provides methods for preventing or treating illness, improving responsiveness to immunization, and improving the efficacy of gene therapy in a patient by disrupting sex steroid signalling in the patient, wherein the bone marrow and other immune cell functionality is improved without, prior to, or concurrently with, thymic regeneration. In some embodiments, sex steroid signalling is interrupted or ablated in the patient by the administration of LHRH agonists, LHRH antagonists, anti-LHRH receptor antibodies, anti-LHRH vaccines, anti-androgens, anti-estrogens, selective estrogen receptor modulators (SERMs), selective androgen receptor modulators (SARMs), selective progesterone response modulators (SPRMs), ERDs, aromatase inhibitors, or various combinations thereof.

A medicine combination has the function of resisting lung cancer. The combination is mixed with rhizoma paridis saponin and milk vetch root amylose according to the weight ratio of 3 to 1. The rhizoma paridis is extracted by alcohol and then the rhizoma paridis extract is obtained through gradient elutriation of macroporous absorption resin alcohol; the milk vetch root is extracted by water and then the protein is settled and removed to get the milk vetch root amylose; the two extracts are mixed and the medicine is made. The MTT activities experiment in vitro with the MTT method has proven that the medicine combination can obviously control the growth of various lung cancer cells such as LA795 lung adenocarcinoma cell and the IC₅₀ can reach 26.73 ug/ml; the experiment of mouse with the lung cancer tumor has represented that the tumor constraint rate can reach 55.63 percent; in this way, lung transfer of hypodermic transplanted tumor of the mouse with the lung cancer tumor can be obviously controlled and the tumor cells can be brought to death; moreover, spleen index and thymus index can be promoted and the medicine is innocuous and has no side effect. In addition, compared with the raw materials, the medicine combination has high activity and clear function; moreover, the medicine can be made into different types.

The invention belongs to the field of polypeptide synthesis, and relates to a method for preparing thymalfasin through dipeptide fragment liquid-solid bonding. By means of a liquid phase mode, a dipeptide fragment of continuous amino acid is synthesized, the dipeptide fragment is used for batch charging solid phase synthesis, and the problems that loci are difficult to couple, and a deletion peptide is prone to generation are solved. Meanwhile, purity and yield of crude peptides are increased. The technology is used for preparing the thymalfasin so that the purity of the crude peptides can be over 75%. Compared with the prior art, a synthetic route is simple, the problems that the difficult loci are not easy to couple and the deletion peptide is prone to generation are mainly solved, synthesis cost and purification cost are reduced, and industrial large-scale production is facilitated.

The invention relates to the technical field of antibodies, and especially relates to a human thymus stromal lymphopoietin monoclonal antibody and an application thereof. The TSLP antibody can be specifically combined with hTSLP, has high affinity, and can effectively inhibit the combination of TSLP and a receptor thereof so as to inhibit activation of a downstream signal path and activation of immune cells by TSLP. The TSLP antibody has great significance in detection of the content of hTSLP and allergic asthma, and diagnosis, treatment and prognosis of inflammatory or allergic inflammatory diseases such as chronic obstructive pulmonary disease, allergic dermatitis, allergic rhinitis, allergic nasosinusitis, eosinophilic granulocytic esophagitis, allergic conjunctivitis, inflammatory bowel disease or atopic dermatitis.

The invention discloses lymphocyte antigen epitope peptides and application thereof, belongs to the fields of medical immunology and infectious diseases, and particularly relates to 164 thymus dependent lymphocyte antigen epitope peptides of five proteins of SARS-CoV-2 and application thereof. The antigen epitope peptides can be presented by HLA-A molecules to stimulate activation, proliferation and differentiation of SARS-CoV-2 specific thymus dependent lymphocytes, so that the immune effect of resisting SARS-CoV-2 infection is exerted. The antigen peptides can be used for preparing mixed polypeptide vaccines of SARS-CoV-2, recombinant protein vaccines connected with a plurality of epitope peptides in series and DNA and RNA vaccines, can be used for preparing a detection kit for detecting SARS-CoV-2 specific thymus dependent lymphocytes, can also be used for preparing effector thymus dependent lymphocytes or drugs for treating SARS-CoV-2 infection, and have a potential application value in the prevention, treatment and diagnosis of SARS-CoV-2 infection and COVID-19.

The invention discloses a thymopeptide-5 powder preparation and a preparation method thereof. The method comprises the following steps: dissolving excipient in water to produce solution I, and filtering the solution I to collect filtrate I; adding the thymopeptide-5 to the filtrate I to obtain solution II, and filtering solution II to collect filtrate II; and freezing and drying the filtrate II to obtain the thymopeptide-5 powder preparation. The excipient can be any one of mannite, lactose and glycin. Experiments prove that, in the thymopeptide-5 powder preparation, thymopeptide-5 is not easy to be degraded, and has good solubility; low content of 'related substances' which is below 1.0 percent, so that healing efficacy and safety of the thymopeptide-5 powder preparation can be greatly improved.

The invention provides a thymalfasin sustained-release microsphere preparation and a preparation method thereof. The thymalfasin sustained-release microsphere preparation comprises the following components in percentage by weight: 0.1 to 10 percent of thymalfasin, and 85 to 99 percent of poly(glycolide-co-lactide), wherein the poly(glycolide-co-lactide) is copolymer of glycolide and lactide, the ratio of the glycolide to the lactide is (25:75)-(75:25), the molecular weight of the poly(glycolide-co-lactide) is between 5,000 and 35,000 dalton, and the intrinsic viscosity is between 0.1 and 0.5dL/g. The pH value of the external water phase of the thymalfasin sustained-release microsphere preparation is between 3.0 and 5.0, and can be regulated by adopting acetic acid, hydrochloric acid, sulfuric acid and the like. The inventor discovers that by controlling the pH value of the external water phase, the stability of the thymalfasin can be improved and the entrapment rate in a preparation process also can be improved, so that the drug-loading rate of sustained-release microspheres can be improved.

The invention discloses a medicament for treating geriatric disease, and at the medicament can be used for solving the technical problems of improving the functions of viscera, improving the immunity, invigorating qi and blood, and ensuring not to cause the body of middle-aged and aged people aiming at the geriatric disease. The technical scheme adopted by the invention is as follows: the medicament is characterized by comprising 1 to 5,000g of ants, 1 to 3,000g of glssy ganoderma, and 1 to 500g of pearl. Compared with the prior art, the unique broad-spectrum and immunity dual immunomodulatory action of ants are sufficiently played, the degraded thymus gland is promoted to proliferate, the weight is increased, the lymphocytes in the cortical area are increased, the functions of immunity center are activated, the leucocytes and lysozymes in the blood are increased, and the phagocytosis is improved. The medicament has the functions of nourishing kidney, tonifying spleen and dredging abdomen, tranquilizing by nourishing the heart and promoting blood circulation to remove meridian obstruction, so that the body is restored to a normal metabolizing state to comprehensively treat the geriatric disease. Therefore, the medicament achieves the aims of preventing and treating geriatric disease, delaying aging, improving wisdom and strengthening body, and protecting bodies of middle-aged and aged people from being hurt.

The invention discloses a Chinese hamster ovary culture medium as well as a preparation method and application thereof. The culture medium comprises ascorbic acid, pyridoxine hydrochloride, vitamin B12, nicotinamide, riboflavin, thiamine chloride, choline chloride, folic acid, calcium pantothenate, sodium pyruvate, reduced glutathione, inositol, biotin, hypoxanthine, putrescine, lipoic acid, linoleic acid, thymine, glucose, HEPES (2-hydroxyethyl) buffer solution, dextran sulphate, Pluronic-F68, various amino acids and salts thereof and various inorganic salts. The culture medium has low cost, and the component does not contain animal origin ingredients, does not contain protein and has definite chemical ingredients. All ingredients are cooperated and blended, and the Chinese hamster ovary culture medium can satisfy the basic growth requirement of cells, and can effectively regulate, transfer and control the culture of cells so as to realize good high-density cell culture. Compared with the culture effect of the existing culture medium, the culture effect of culture medium disclosed in the invention is at least equivalent to even superior to the existing culture medium.

The invention relates to the technical field of medicament, in particular to inonotus obliquus extracellular and intracellular mixing crude polysaccharide with a function of strengthening immunity, which is extracted from a submerged fermentation product of medical fungus inonotus obliquus liquid. The method comprises the following steps: taking slant strain under an asepsis condition, and inoculating the slant strain into a plate filled with fresh comprehensive solid culture medium; pumping and filtering a secondary fermentation product through primary fermentation and secondary fermentation to obtain inonotus obliquus mycelium and fermentation supernatant; and preparing the inonotus obliquus extracellular and intracellular mixing crude polysaccharide through concentration and water extraction and alcohol precipitation. In vivo experiments prove that the inonotus obliquus extracellular and intracellular mixing crude polysaccharide can prolong the surviving time of mice hepatocellular carcinoma H22 and S180 ascites tumor mice, and can obviously improve the thymus gland index and spleen index of the mice. Furthermore, the inonotus obliquus extracellular and intracellular mixing crude polysaccharide can obviously improve secretion of IL-2, TNF-alpha cell factors in the blood serum of the tumor-bearing mice, and can be used for preparing new immunity intensifying preparation. The invention opens up a new way for development and utilization of medical fungus resources.

The invention discloses a mesenchymal stem cell and the application thereof in resisting HIV-1 (human immunodeficiency virus), and particularly relates to a mesenchymal stem cell of a secreted-expression high-concentration keratinocyte growth factor (KGF), and the mesenchymal stem cell is produced through a micro-carrier culturing system. According to the invention, the mesenchymal stem cell can be used for promoting the development of the thymus gland, maintaining the functions of the thymus gland, and enhancing the immunologic function of specific T cells through increasing the output of T lymphocytes to peripheral blood, thereby achieving an effect of treating HIV-1 infection, and providing an effective new strategy for the clinical treatment of the acquired immunodeficiency syndrome.

The invention discloses separation and application of a high-lysis-rate salmonella phage RDP-SA-17118. The host of the salmonella phage RDP-SA-17118 is salmonella S6, and the phage can form a plaque with a diameter of 2mm-4mm on double plates. Through observation by an electron microscope, the phage has a polyhedral stereosymmetric head which wraps nucleic acid and has a diameter of 70nm; the phage has a tail with a length of 120nm and has a tail sheath; a neck is connected with the head and the tail; and the phage belongs to myoviridae of caudovirales. The phage has a high titer of 10<12> pfu/mL and has good tolerance to temperature and pH value, and the titer still keeps 10<12>pfu/mL or above after continuous passage for 29 times. The phage has a good lysis effect on a host after being diluted by 10<6> times, and after the phage is fed, existence of the phage can be detected in heart, liver, lung, kidney, thymus and serum. Through animal experiments, the phage has a good effect in treating chicken salmonella diseases.

A method of purifying a subpopulation of naive T cells that have recently emigrated from the thymus, comprising (a) contacting a biological sample susceptible of containing T cells with at least four different ligands, namely ligands directed to the markers CD3, CD4, CD45RA, and CD31; (b) sorting the cells so as to recover T cells having a phenotype comprising at least the following four markers CD3⁺, CD4⁺, CD45RA⁺ and CD31^hi, whereby a subpopulation of naive T cells is purified.

The invention provides a slow release microsphere agents, comprising thymosin Alpha 1 of 0.5% to 10% of the microsphere weight, degradable pharmaceutical macromolecular accessories with a molecular weight of 5,000 to 500,000 Dalton and of 70% to 99.5% of the macroshpere weight, and 0% to 10% of other pharmaceutically acceptable accessories. The invention also provides the preparation method of the slow release microsphere agents. The slow release microsphere agent of thymosin Alpha 1 for injection has the advantages that the poison and side effect of thymosin Alpha 1 is reduced; the bioavailability is enhanced; times for drug taking is reduced and the drug can be conveniently taken by patients.

The invention relates to a feed, and in particular relates to compound premix for quick delivery and postpartum recovery of a sow and a preparation process thereof. The compound premix consists of a thymus extract, a rabbit muscle extract, brown sugar and the like, and is green compound premix which is free from substances leading to carcinogenesis, teratogenesis and mutagenesis. The premix has the effects of accelerating the sow for quick delivery and promoting postpartum recovery, enhancing the immunity of animals, improving the disease resistance of animals and reducing the incidence of the disease of a piglet.